8 assets in Cancer Or Benign Tumor

Therapeutic assets addressing Cancer Or Benign Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Cancer Or Benign Tumor	Emory University	P1	CCC (55)
Cabozantinib Cancer Or Benign Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Cancer Or Benign Tumor	Children's Oncology Group	P2	CCC (53)
Veliparib Cancer Or Benign Tumor	National Cancer Institute (NCI)	P1	CCC (52)
Adriamycin Cancer Or Benign Tumor	National Cancer Institute (NCI)	P1	CC (43)
Cyclophosphamide Cancer Or Benign Tumor	Mayo Clinic	P1	CC (43)
Pazopanib Cancer Or Benign Tumor	National Cancer Institute (NCI)	P1	CC (43)
Sapanisertib Cancer Or Benign Tumor	National Cancer Institute (NCI)	P1	CC (43)